INOVIQ Ltd (EGQ0.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 08:00AM CEST
| Previous close | 0.3040 |
| Open | 0.3020 |
| Bid | 0.3080 x N/A |
| Ask | 0.3420 x N/A |
| Day's range | 0.3020 - 0.3020 |
| 52-week range | 0.2620 - 0.5550 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 29.335M |
| Beta (5Y monthly) | 2.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
EXCELLENT CLINICAL DATA FOR SUBB2M/CA15-3 BREAST CANCER TEST
INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a developer of next-generation exosome solutions and precision diagnostics, is pleased to announce excellent results from an independent clinical validation study of its SubB2M/CA15-3 test for breast cancer detection. The study showed high accuracy (87%), sensitivity (81%), and specificity (93%) for INOVIQ's SubB2M test, outperforming a leading approved CA15-3 test.
© 2024 Yahoo. All rights reserved.